3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
4
Carcinoma, Squamous Cell
2
Recurrence
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Lymphoid Interstitial Pneumonia
1
Lip Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma
1
Interventions
pembrolizumab
35
Cetuximab
18
Gemcitabine
14
Nivolumab
13
Cisplatin
13
Paclitaxel
10
Carboplatin
9
Cyclophosphamide
7
cemiplimab
6
Fluorouracil
6
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Docetaxel
5
fludarabine
4
durvalumab
4
aldesleukin
4
Immune Checkpoint Inhibitors
4
Biopsy
4
fludarabine phosphate
3
Valproic Acid
3
Radiation
3
Interleukin-2
3
Drug Therapy
3
Bevacizumab
3
130-nm albumin-bound paclitaxel
3
tislelizumab
2
sintilimab
2
avelumab
2
apatinib
2
Tablets
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
ficlatuzumab
×
Head & Neck
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled